The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

Phase I

10004: A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL). NCI Center for Cancer Research; Waldmann, Thomas Alexander. (301) 496-6656

9882: Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2’- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers. Rhode Island Hospital; Kinsella, Timothy James. (401) 444-6203

Phase II

AOST1521: A Phase 2 Study of GPNMB-Targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; IND# 128248, NSC# 763737), in Recurrent or Refractory Osteosarcoma. Children’s Oncology Group; Kopp, Lisa M. (520) 626-2021

Other Phases

AALL15B2-Q: Use of DNA Methylation Assessment by xMELP for Prognosis in Pediatric Patients with T-ALL. Children’s Oncology Group; Wertheim, Gerald. (267) 970-5918

AALL15B7-Q: Role of the MAPK/ERK Pathway in Relapsed Pediatric B-Lymphoblastic Leukemia: Prognostic Implications and Potential for Targeted Therapy. Children’s Oncology Group; Carroll, William L. (212) 263-9947

ANHL15B1-Q: B-Lineage Lymphoblastic Lymphoma SNP Array Profiling. Children’s Oncology Group; Miles, Rodney R. (801) 213-3448

AREN15B2-Q: Mapping Endogenous Mobile Elements in Rhabdoid Tumors. Children’s Oncology Group; Kentsis, Alex. (646) 888-2593

ARST15B2-Q: Validation of Anti-FGFR4 Antibodies as Potential Therapeutic Agents for Rhabdomyosarcoma. Children’s Oncology Group; Khan, Javed. (301) 439-2937

ARST15B4-Q: Infantile Rhabdomyosarcoma. Children’s Oncology Group; Arnold, Michael Andrew. (614) 722-5719

S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Pragmatic Traisl Assessing CSF Prescribing Effectiveness and Risk (TRACER). SWOG; Ramsey, Scott David. (206) 667-7846